Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITAR HDM subcutaneous allergen immunotherapy study in persistent allergic rhinitis
TCTR20140127001Phase 3Active, not recruiting
- Sponsor
- National Research Council Canada
- Start
- Feb 2014
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of House dust mite allergen extract in allergic rhinitis (AR), sponsored by National Research Council Canada. Started Feb 2014; status: active, not recruiting.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on TCTR20140127001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20140127001.